Back to results
US 12,208,126 B2Granted
Oncolytic viral vectors and uses thereof
AssigneeVirogin Biotech Canada Ltd
InventorsMitchell H. Finer, Lorena Lerner, Christophe Quéva, Edward Kennedy
Life of this patent
Estimating the term…
Abstract
Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.
Claims23
A recombinant oncolytic herpes simplex virus (HSV) comprising
- (i) a first micro-RNA (miRNA) target sequence cassette (miR-TS) cassette inserted into at least one ICP4 gene or at least one ICP4 untranslated region (UTR) and comprising at least 2 target sequences for each of miR-124, miR-1, and miR-143;
- (ii) a second miR-TS cassette inserted into the ICP27 gene or an ICP27 untranslated region (UTR) and comprising at least 2 target sequences for each of miR-128, miR-219a, and miR-122;
- and
- (iii) a third miR-TS cassette inserted into at least one ICP34.5 gene or at least one ICP34.5 untranslated region (UTR) and comprising at least 2 target sequences for each of miR-219a, miR-204, and miR-128.
1 more element
Dependencies are inferred from the claim text.